Combination Antibody Therapy Market - High Growth by 2016 - 2022
Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors.
Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
<br />
<br />
o Ipilimumab and Bevacizumab<br />
o Others<br />
Segmentation <strong>by</strong> Route of administration<br />
o Oral<br />
o Parenteral<br />
Segmentation <strong>by</strong> End User<br />
o Hospitals<br />
o Ambulatory Surgical Centers<br />
o Cancer institutions<br />
o Clinical research institutes<br />
Primary revenue drivers for combination antibody therapy are an increase in number of patients seeking safe and<br />
chemotherapy free treatment. <strong>High</strong> rate of cancer in human population globally, is estimated to affect significantly in<br />
combination antibody therapy market worldwide. Other revenue drivers include life style changes and rise in adulterated<br />
food consumption <strong>by</strong> individuals. Furthermore, the combination antibody therapy market is expected to grow on the<br />
backdrop of rise in cases of skin tumors, which includes basal cell and squamous cell carcinomas and make up 12% of<br />
all skin tumors.<br />
On the basis of region presence, <strong>Combination</strong> antibody therapy market is segmented into five key regions: North<br />
America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Currently, North America dominates the global<br />
market for <strong>Combination</strong> antibody therapy due to high adoption and diagnosis rate, followed <strong>by</strong> Europe. Rising number<br />
of cancer patients is expected to fuel the <strong>Combination</strong> antibody therapy market. <strong>Combination</strong> antibody therapy market<br />
in Asia Pacific and Middle East and Africa is expected to register high growth due to developing healthcare infrastructure<br />
and high prevalence of tumor and cancer.<br />
Some of the major market players in <strong>Combination</strong> antibody therapy market globally include Laboratory Corporation of<br />
EMD Millipore Corporation, Thermo Fisher Scientific Inc., GeneTex Inc., Novus Biologicals, BioLegend, Inc., PDL<br />
BioPharma, Inc, Fortress Biotech., Peregrine Pharmaceuticals Inc., Cellerant Therapeutics, Inc., Aspyrian<br />
Therapeutics, Inc. The report covers exhaustive analysis on:<br />
<strong>Combination</strong> antibody therapy <strong>Market</strong> Segments<br />
<strong>Combination</strong> antibody therapy <strong>Market</strong> Dynamics<br />
Historical Actual <strong>Market</strong> Size, 2014 - 2015<br />
<strong>Combination</strong> antibody therapy <strong>Market</strong> Size & Forecast <strong>2016</strong> to <strong>2022</strong><br />
<strong>Combination</strong> antibody therapy Current Trends/Issues/Challenges<br />
Competition & Companies involved<br />
<strong>Combination</strong> antibody therapy Drivers and Restraints<br />
Request to view Sample Report : http://www.persistencemarketresearch.com/samples/11740<br />
Regional analysis includes<br />
North America<br />
Latin America<br />
Europe<br />
Asia Pacific<br />
Middle East & Africa<br />
Report <strong>High</strong>lights:<br />
Shifting Industry dynamics<br />
In-depth market segmentation<br />
Historical, current and projected industry size Recent industry trends<br />
Key Competition landscape<br />
Strategies of key players and product offerings<br />
<strong>Combination</strong> <strong>Antibody</strong> <strong>Therapy</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |
Change language